Hansa
-
Endelig sker der lidt, udover konferencer. Godt nok først opstart i 2022, men bedre end ingenting:
https://investors.hansabiopharma.com/English/press-releases/press-releases-details/2021/Hansa-Biopharma-to-initiate-Phase-3-study-of-imlifidase-to-treat-anti-Glomerular-Basement-Membrane-anti-GBM-disease-after-successful-pre-IND-meeting-with-U.S.-FDA/default.aspx -
Du er ikke den eneste
Hansa Biopharma; FDA opens the door for the next pivotal Phase 3 study
Uddrag: "In our view, Hansa Biopharma’s ability to progress the progress of the anti-GBM opportunity for the imlifidase platform is distinctly positive. This follows a successful pre-IND meeting with the FDA. Recently we have seen several FDA delays in this sector, and Hansa’s ability to timely progress this candidate to the third pivotal Phase 3 trial is an achievement."
"....... Our base case value proposition is SEK 410 (Bear SEK 175 and Bull SEK 600)."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind